Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

Keyphrases

• Adverse Events 100%
• All Pediatric 25%
• Cancer Mortality 25%
• Capillary Leak Syndrome 25%
• Chemotherapy 25%
• Clinical Practice 25%
• Combined Modality Therapy 50%
• Differentiation Therapy 25%
• Dinutuximab 100%
• Disialoganglioside 50%
• Europe 25%
• European Medicines Agency 25%
• Extracranial Solid Tumor 25%
• Fever 25%
• Hematopoietic Stem Cell Differentiation 25%
• Hematopoietic Stem Cell Rescue 25%
• High-dose Chemotherapy 25%
• High-risk Neuroblastoma 100%
• International Society 25%
• Neuroblastoma 50%
• Patient Demographics 25%
• Pediatric Cancer 25%
• Pediatric Oncology 25%
• Practical Guidance 100%
• Radiotherapy 25%
• Rescue Therapy 25%
• Standard of Care 25%
• Survival Rate 25%
• Treatment Regimen 25%
• Tumors in children 25%

Medicine and Dentistry

• Adverse Event 100%
• Allergic Response 16%
• Cancer Mortality 16%
• Capillary Leak Syndrome 16%
• Chemotherapy 16%
• Childhood Cancer 16%
• Clinician 50%
• Differentiation Therapy 16%
• Dinutuximab 100%
• Diseases 16%
• Ganglioneuroblastoma 100%
• Hematopoietic Cell 16%
• High Dose Chemotherapy 16%
• Immunotherapy 33%
• Patient Population 16%
• Pediatric Cancer 16%
• Radiation Therapy 16%
• Solid Malignant Neoplasm 16%
• Survival Rate 16%